NCT00311623 Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer Status COMPLETED Phase PHASE1/PHASE2
NCT00310479 Clinico-pathologic Correlative Study of 3T Magnetic Resonance Spectroscopy in the Localization of Prostate Cancer Status COMPLETED Phase NA
NCT00309894 Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy Status COMPLETED Phase PHASE2
NCT00307294 Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC) Status COMPLETED Phase PHASE2
NCT00305929 Study of WST09 in Prostate Cancer After Radiation: Repeat Procedure Status COMPLETED Phase PHASE2
NCT00305747 Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy Status COMPLETED Phase PHASE1
NCT00305669 GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer Status COMPLETED Phase PHASE1
NCT00303914 Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer Status COMPLETED Phase N/A
NCT00303875 Exercise and Dietary Counseling in Improving Physical Activity, Nutrition, and Quality of Life in Older Long-Term Cancer Survivors Who Are Overweight Status COMPLETED Phase PHASE2
NCT00295802 Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer Status UNKNOWN Phase PHASE2/PHASE3
NCT00295750 The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer Status COMPLETED Phase PHASE3
NCT00294437 ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases Status TERMINATED Phase PHASE3
NCT00294151 Potential Vertebroplasty Use in the Treatment of Vertebral Metastasis From Breast and Prostate Cancer Status UNKNOWN Phase PHASE3
NCT00293371 Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer Status TERMINATED Phase PHASE1/PHASE2
NCT00292045 Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer Status COMPLETED Phase PHASE1